Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 298

1.

Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-mitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms.

Kim JY, Son JY, Lee BM, Kim HS, Yoon S.

Anticancer Res. 2018 Sep;38(9):5149-5157. doi: 10.21873/anticanres.12837.

PMID:
30194162
2.

Low Doses of the Anti-psychotic Drug Aripiprazole Have Strong P-gp-inhibitory Activity and Sensitize Anti-mitotic Drug-resistant Cancer Cells.

Kim JY, Tae IH, Lee BM, Kim HS, Yoon S.

Anticancer Res. 2018 Sep;38(9):5101-5108. doi: 10.21873/anticanres.12830.

PMID:
30194155
3.

[A Case of Recurrent Breast Cancer with Complete Response to Eribulin Monotherapy after Bevacizumab plus Paclitaxel Combination Therapy].

Higashi T, Ozawa K, Takagi S, Onodera Y, Yokoyama M, Mase K, Moriya T, Takeshita A, Mizutani M, Usuba O.

Gan To Kagaku Ryoho. 2018 Jul;45(7):1093-1095. Japanese.

PMID:
30042279
5.

Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.

Giordano G, Febbraro A, Quaquarini E, Turletti A, Pedersini R, Raffaele M, Villa F, Rossello R; The Italian Eribulin Working Group.

Oncology. 2018;94 Suppl 1:34-44. doi: 10.1159/000489067. Epub 2018 Jul 24.

6.

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Catania G, Malaguti P, Gasparro S, Cognetti F, Vidiri A, Fabi A.

Oncology. 2018;94 Suppl 1:29-33. doi: 10.1159/000489066. Epub 2018 Jul 24.

7.

Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.

De Sanctis R, Agostinetto E, Masci G, Ferraro E, Losurdo A, Viganò A, Antunovic L, Zuradelli M, Torrisi RMC, Santoro A.

Oncology. 2018;94 Suppl 1:19-28. doi: 10.1159/000489065. Epub 2018 Jul 23.

8.

Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.

Nettuno R, Menditto C.

Oncology. 2018;94 Suppl 1:16-18. doi: 10.1159/000489064. Epub 2018 Jul 23.

9.

Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.

Pedersini R, Vassalli L, Claps M, Tulla A, Rodella F, Grisanti S, Amoroso V, Roca E, Simoncini EL, Berruti A.

Oncology. 2018;94 Suppl 1:10-15. doi: 10.1159/000489063. Epub 2018 Jul 23.

10.

Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report.

Medici M, Fossile E.

Oncology. 2018;94 Suppl 1:3-5. doi: 10.1159/000489061. Epub 2018 Jul 23.

11.

Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement.

Dottorini L, Catena L, Sarno I, Di Menna G, Marte A, Bajetta E.

Oncology. 2018;94 Suppl 1:6-9. doi: 10.1159/000489062. Epub 2018 Jul 23.

12.

[Peripheral neuropathy as a side effect of chemotherapy and targeted therapy].

Gießen-Jung C, von Baumgarten L.

Dtsch Med Wochenschr. 2018 Jul;113(13):970-978. doi: 10.1055/s-0043-120839. Epub 2018 Jul 4. Review. German.

PMID:
29972842
13.

Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.

Sakaguchi K, Nakatsukasa K, Koyama H, Kato M, Sakuyama A, Matsuda T, Tsunoda N, Fujiwara I, Yamaguchi M, Tanaka H, Onishi K, Onishi M, Yoshino Y, Kikuchi T, Taguchi T.

Anticancer Res. 2018 Jul;38(7):4073-4081. doi: 10.21873/anticanres.12697.

PMID:
29970533
14.

Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy.

Zhao B, Zhao H, Zhao J.

Crit Rev Oncol Hematol. 2018 Aug;128:110-117. doi: 10.1016/j.critrevonc.2018.06.003. Epub 2018 Jun 12. Review.

PMID:
29958626
15.

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data.

Kawamura T, Kasai H, Fermanelli V, Takahashi T, Sakata Y, Matsuoka T, Ishii M, Tanigawara Y.

Cancer Sci. 2018 Sep;109(9):2822-2829. doi: 10.1111/cas.13708. Epub 2018 Jul 23.

16.

Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.

Asano M, Matsui J, Towle MJ, Wu J, McGonigle S, DE Boisferon MH, Uenaka T, Nomoto K, Littlefield BA.

Anticancer Res. 2018 Jun;38(6):3375-3385. doi: 10.21873/anticanres.12604.

PMID:
29848686
17.

Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.

Miki S, Imamichi S, Fujimori H, Tomiyama A, Fujimoto K, Satomi K, Matsushita Y, Matsuzaki S, Takahashi M, Ishikawa E, Yamamoto T, Matsumura A, Mukasa A, Nishikawa R, Masutomi K, Narita Y, Masutani M, Ichimura K.

Cancer Sci. 2018 Jul;109(7):2275-2285. doi: 10.1111/cas.13637. Epub 2018 Jun 19.

18.

Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.

Goto W, Kashiwagi S, Asano Y, Takada K, Morisaki T, Fujita H, Takashima T, Ohsawa M, Hirakawa K, Ohira M.

Anticancer Res. 2018 May;38(5):2929-2938.

PMID:
29715119
19.

Experience with eribulin in patients with breast cancer and cutaneous metastases: case studies.

Espinosa Aunión R, Ramírez Ruda CA, Rodríguez López C, Curiel García T, García Saénz JÁ, López López R.

Future Oncol. 2018 Mar;14(7s):37-44. doi: 10.2217/fon-2017-0360.

PMID:
29611759
20.

Experience with eribulin in the treatment of elderly women with metastatic breast cancer: case studies.

Garrido ML, Morago AJ, Rovira PS, Olarte PE, Sánchez CP, Sánchez LM.

Future Oncol. 2018 Mar;14(7s):21-27. doi: 10.2217/fon-2017-0357.

PMID:
29611758

Supplemental Content

Loading ...
Support Center